NO924723D0 - Farmakologisk anvendelse av visse cystinderivater - Google Patents

Farmakologisk anvendelse av visse cystinderivater

Info

Publication number
NO924723D0
NO924723D0 NO924723A NO924723A NO924723D0 NO 924723 D0 NO924723 D0 NO 924723D0 NO 924723 A NO924723 A NO 924723A NO 924723 A NO924723 A NO 924723A NO 924723 D0 NO924723 D0 NO 924723D0
Authority
NO
Norway
Prior art keywords
cystin
derivatives
certain
pharmacological use
pharmacological
Prior art date
Application number
NO924723A
Other languages
English (en)
Other versions
NO924723L (no
Inventor
Carl Magnus Aleksand Andersson
Sten Haakan Axel Bergstrand
Anders Rudolf Hallberg
Bengt Olof Saernstrand
Per Anders Sigvard Tunek
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9002067A external-priority patent/SE9002067D0/xx
Priority claimed from SE9002275A external-priority patent/SE9002275D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of NO924723L publication Critical patent/NO924723L/no
Publication of NO924723D0 publication Critical patent/NO924723D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO924723A 1990-06-08 1992-12-07 Farmakologisk anvendelse av visse cystinderivater NO924723D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9002067A SE9002067D0 (sv) 1990-06-08 1990-06-08 The pharmacological use of certain cystine derivatives
SE9002275A SE9002275D0 (sv) 1990-06-28 1990-06-28 Novel 3,3'-dithiobis(propionic acids)
PCT/SE1991/000388 WO1991018594A1 (en) 1990-06-08 1991-06-03 The pharmacological use of certain cystine derivatives

Publications (2)

Publication Number Publication Date
NO924723L NO924723L (no) 1992-12-07
NO924723D0 true NO924723D0 (no) 1992-12-07

Family

ID=26660796

Family Applications (1)

Application Number Title Priority Date Filing Date
NO924723A NO924723D0 (no) 1990-06-08 1992-12-07 Farmakologisk anvendelse av visse cystinderivater

Country Status (20)

Country Link
US (2) US5441976A (no)
EP (1) EP0532595B1 (no)
JP (1) JP3204320B2 (no)
KR (1) KR100236253B1 (no)
AT (1) ATE144705T1 (no)
AU (1) AU652946B2 (no)
CA (1) CA2083274C (no)
DE (1) DE69122961T2 (no)
DK (1) DK0532595T3 (no)
HK (1) HK62597A (no)
HU (1) HU215920B (no)
IE (1) IE80754B1 (no)
IL (1) IL98310A (no)
LV (2) LV10186B (no)
NO (1) NO924723D0 (no)
NZ (1) NZ247658A (no)
PT (1) PT97905B (no)
RU (1) RU2119793C1 (no)
SG (1) SG49736A1 (no)
WO (1) WO1991018594A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9018994D0 (en) * 1990-08-31 1990-10-17 Secr Defence Toxic agent protective compounds
US5889050A (en) * 1991-06-21 1999-03-30 Astra Aktiebolag 3,3'-dithiobis (propionic acids) and esters thereof
SE9103572D0 (sv) * 1991-11-29 1991-11-29 Astra Ab Organic salts of n,n'-diacetyl cystine
JP2947044B2 (ja) * 1993-01-27 1999-09-13 味の素株式会社 免疫不全症候群治療の補助療法剤
DE4329857C2 (de) * 1993-09-03 1995-08-24 Deutsches Krebsforsch Verbindung zur Stärkung des Immunsystems und von Immunreaktionen
SE9500897D0 (sv) * 1995-03-14 1995-03-14 Astra Ab The pharmacological use of certain cystine derivatives
SE9501067D0 (sv) * 1995-03-24 1995-03-24 Astra Ab New peptides
SE9602262D0 (sv) * 1996-06-06 1996-06-06 Astra Ab New use of derivatives of cystine
US6197749B1 (en) 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
US20030203006A1 (en) * 1997-10-29 2003-10-30 Ajinomoto Co. Inc. Immunomodulator
KR20010075000A (ko) * 1998-10-09 2001-08-09 에가시라 구니오 시스테인 유도체
EP1004302A3 (en) * 1998-10-29 2003-06-04 Ajinomoto Co., Inc. Immunomodulator
SE9900438D0 (sv) * 1999-02-10 1999-02-10 Astra Ab The pharmacological use of certian cystine derivatives
JP3988014B2 (ja) * 2000-02-02 2007-10-10 味の素株式会社 ウイルス感染症予防剤
ATE517607T1 (de) 2000-11-30 2011-08-15 Vectura Ltd Verfahren zur herstellung von partikeln zur verwendung in einer pharmazeutischen zusammensetzung
SE518784C2 (sv) * 2000-12-27 2002-11-19 Nactilus Ab "N-Acetyl-L-cystein med kompositioner för behandling av neoplasier"
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
DE102004043055B4 (de) 2004-09-06 2009-04-02 Siemens Ag Führungsvorrichtung zur Führung eines bewegbaren Maschinenelementes einer Maschine
EP2068903A4 (en) * 2006-10-03 2010-11-03 Galleon Pharmaceuticals Inc S-NITROSOTHIOL COMPOUNDS AND RELATED DERIVATIVES
JP2010535705A (ja) * 2007-04-23 2010-11-25 シガ テクノロジーズ，インコーポレーテッド オルソポックスウイルス感染及び関連疾患の治療及び予防のための化学物質、組成物、及び方法
US7829709B1 (en) 2007-08-10 2010-11-09 Marquette University Cysteine prodrugs to treat schizophrenia and drug addiction
US8173809B2 (en) 2008-02-07 2012-05-08 Marquette University Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings
CN106232577B (zh) 2014-04-25 2019-02-22 味之素株式会社 免疫刺激剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR8205M (no) * 1968-12-20 1970-09-14
US3878305A (en) * 1972-05-25 1975-04-15 Procter & Gamble Fortification of foodstuffs with n-acyl derivatives of sulphur-containing l-amino acids
US3952115A (en) * 1975-04-02 1976-04-20 The Procter & Gamble Company Fortification of foodstuffs with N-acyl derivatives of sulfur-containing L-amino acid esters
GB2097256B (en) * 1981-04-02 1985-05-30 Morelle Jean V Compositions containing n-butyryl alphaaminoacids
FR2503151A1 (fr) * 1981-04-02 1982-10-08 Morelle Jean Butyryminoacides soufres. mode de preparation. emploi comme element keratogenique chez l'homme et l'animal et comme agent de fertilisation chez les vegetaux
US4827016A (en) * 1985-09-16 1989-05-02 Morgan Lee R Method and compounds for reducing dermal inflammations
US4708965A (en) * 1985-09-16 1987-11-24 Morgan Lee R Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives
US4724239A (en) * 1985-09-16 1988-02-09 Morgan Lee R Method of treating chemical ulcers with N,N'-diacetylcystine, N-acetyl homocysteine and N-acetyl cysteine
IT1249650B (it) * 1991-05-29 1995-03-09 Poli Ind Chimica Spa N-(5-tioxo-l-prolil)-l-cisteina e suoi derivati, loro preparazione ed impiego terapeutico

Also Published As

Publication number Publication date
NZ247658A (en) 2000-07-28
US5441976A (en) 1995-08-15
CA2083274C (en) 2002-05-28
EP0532595A1 (en) 1993-03-24
AU8094191A (en) 1991-12-31
RU2119793C1 (ru) 1998-10-10
IE80754B1 (en) 1999-01-13
PT97905A (pt) 1992-03-31
WO1991018594A1 (en) 1991-12-12
LV10186A (lv) 1994-10-20
CA2083274A1 (en) 1991-12-09
AU652946B2 (en) 1994-09-15
IL98310A (en) 1996-08-04
DE69122961T2 (de) 1997-03-13
LV11985B (en) 1998-06-20
DK0532595T3 (da) 1997-04-07
PT97905B (pt) 1998-10-30
NO924723L (no) 1992-12-07
HU215920B (hu) 1999-03-29
US5780508A (en) 1998-07-14
HU9203871D0 (en) 1993-03-29
IE911945A1 (en) 1991-12-18
LV10186B (en) 1995-08-20
SG49736A1 (en) 1998-06-15
HK62597A (en) 1997-05-16
KR100236253B1 (ko) 1999-12-15
JPH05507705A (ja) 1993-11-04
LV11985A (lv) 1998-03-20
HUT70055A (en) 1995-09-28
IL98310A0 (en) 1992-06-21
DE69122961D1 (de) 1996-12-05
JP3204320B2 (ja) 2001-09-04
EP0532595B1 (en) 1996-10-30
ATE144705T1 (de) 1996-11-15

Similar Documents

Publication Publication Date Title
NO924723L (no) Farmakologisk anvendelse av visse cystinderivater
NO884154L (no) Fremgangsmaate for fremstilling av terapeutisk aktive preparater.
NO883974L (no) Fremgangsmaate for fremstilling av terapeutiske aktive tetrahydro-hydroksypyranon-derivater.
NO904986L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive diazepin-derivater.
NO910935D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive c-bundne pyrazol-derivater.
NO874955D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heteroaromatiske aminderivater.
NO874153D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazo-benzoksazinon-derivater.
NO903941D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive diazepinon-derivater.
NO911065L (no) Fremgangsmaate for fremstilling av lipopeptidderivater.
NO167734C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte aminderivater.
SE9403137D0 (sv) Derivatives of carbohydrates and compositions containing them
NO891009L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzocyklokeptenderivater.
NO167802C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzotiazepinderivater.
NO913644D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
FI951092A (fi) Fluoreseiinijohdannaisten stabiilit korkeakonsentroidut valmisteet
NO874780D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolo-benzimidazol-derivater.
NO930452D0 (no) Nye farmasoeytiske preparater av 5-(2-klor-1-hydroksyetyl)-4-metyltiazol
NO900972D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater.
ES2184121T3 (es) Formulacion para el tratamiento y/o profilaxis de la demencia.
NO900942D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive azacyklooktadien-derivater.
NO900812L (no) Fremgangsmaate for fremstilling av terapeutisk aktive laktamderivater.
SE9203296D0 (sv) The use of inositoltrisphate for the preparing of medicaments
NO900319L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 9-amino-1,2,3,4-tetrahydroakridinderivater.
NO890506L (no) Fremgangsmaate for fremstilling av terapeutisk aktive kloranilin-derivater.
NO891677L (no) Fremgangsmaate for fremstilling av terapeutisk aktive fenetanolamin-derivater.